HOWL
Undervalued by 101.9% based on the discounted cash flow analysis.
Market cap | $88.72 Million |
---|---|
Enterprise Value | $14.81 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $-1.05 |
Beta | 0.46 |
Outstanding Shares | 43,521,406 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -1.64 |
---|---|
PEG | -1.62 |
Price to Sales | - |
Price to Book Ratio | 0.8 |
Enterprise Value to Revenue | 4.37 |
Enterprise Value to EBIT | -0.23 |
Enterprise Value to Net Income | -1 |
Total Debt to Enterprise | 2.5 |
Debt to Equity | 0.51 |
No data
No data
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its proprietary PRE...